Abionyx Pharma (France) Performance
| ABNX Stock | EUR 1.31 0.02 1.50% |
Abionyx Pharma has a performance score of 4 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.69, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Abionyx Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Abionyx Pharma is expected to be smaller as well. Abionyx Pharma SA right now shows a risk of 2.64%. Please confirm Abionyx Pharma SA information ratio, total risk alpha, and the relationship between the coefficient of variation and jensen alpha , to decide if Abionyx Pharma SA will be following its price patterns.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Abionyx Pharma SA are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Abionyx Pharma may actually be approaching a critical reversion point that can send shares even higher in February 2025. ...more
| Begin Period Cash Flow | 9.2 M | |
| Total Cashflows From Investing Activities | 1.3 M |
Abionyx |
Abionyx Pharma Relative Risk vs. Return Landscape
If you would invest 124.00 in Abionyx Pharma SA on October 22, 2024 and sell it today you would earn a total of 9.00 from holding Abionyx Pharma SA or generate 7.26% return on investment over 90 days. Abionyx Pharma SA is generating 0.1468% of daily returns and assumes 2.641% volatility on return distribution over the 90 days horizon. Simply put, 23% of stocks are less volatile than Abionyx, and 98% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Abionyx Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Abionyx Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Abionyx Pharma SA, and traders can use it to determine the average amount a Abionyx Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0556
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | ABNX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.64 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Abionyx Pharma is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Abionyx Pharma by adding it to a well-diversified portfolio.
Abionyx Pharma Fundamentals Growth
Abionyx Stock prices reflect investors' perceptions of the future prospects and financial health of Abionyx Pharma, and Abionyx Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Abionyx Stock performance.
| Return On Equity | -0.92 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (1.78) % | |||
| Operating Margin | (1.78) % | |||
| Current Valuation | 51.58 M | |||
| Shares Outstanding | 28.09 M | |||
| Price To Earning | 17.78 X | |||
| Price To Book | 5.91 X | |||
| Price To Sales | 15.30 X | |||
| Revenue | 675 K | |||
| EBITDA | (5.7 M) | |||
| Cash And Equivalents | 8.33 M | |||
| Cash Per Share | 0.38 X | |||
| Total Debt | 3.9 M | |||
| Debt To Equity | 0.18 % | |||
| Book Value Per Share | 0.31 X | |||
| Cash Flow From Operations | (6.69 M) | |||
| Earnings Per Share | (0.21) X | |||
| Total Asset | 21.83 M | |||
About Abionyx Pharma Performance
By analyzing Abionyx Pharma's fundamental ratios, stakeholders can gain valuable insights into Abionyx Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Abionyx Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Abionyx Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein therapies for the treatment of cardiovascular and metabolic diseases. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France. ABIONYX PHARMA is traded on Paris Stock Exchange in France.Things to note about Abionyx Pharma SA performance evaluation
Checking the ongoing alerts about Abionyx Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Abionyx Pharma SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Abionyx Pharma SA may become a speculative penny stock | |
| The company reported the revenue of 675 K. Net Loss for the year was (5.82 M) with profit before overhead, payroll, taxes, and interest of 259 K. | |
| Abionyx Pharma SA has accumulated about 8.33 M in cash with (6.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Roughly 32.0% of the company shares are held by company insiders |
- Analyzing Abionyx Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Abionyx Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Abionyx Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Abionyx Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Abionyx Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Abionyx Pharma's stock. These opinions can provide insight into Abionyx Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Abionyx Stock analysis
When running Abionyx Pharma's price analysis, check to measure Abionyx Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abionyx Pharma is operating at the current time. Most of Abionyx Pharma's value examination focuses on studying past and present price action to predict the probability of Abionyx Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abionyx Pharma's price. Additionally, you may evaluate how the addition of Abionyx Pharma to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |